– USA, PA – PMV Pharmaceuticals, Inc., announced the appointment of renowned biotechnology business leader, Steven Holtzman to the board of directors. Mr. Holtzman’s appointment brings the total board to five members as he joins current members Arnold Levine, Ph.D., David Mack, Ph.D., Arnold Oronsky, Ph.D. and Douglas Fisher, M.D.
“The addition of Steve Holtzman to our Board provides us with important strategic insights as we look to develop our cancer and infectious disease therapeutics. Steve’s proven business and commercial expertise will be of great value as our product portfolio continues to mature,” David Mack, Ph.D., President and CEO of PMV Pharmaceuticals said.
PMV Pharma is pioneering the discovery and development of p53 targeted small molecule drugs for the treatment of cancer and infectious disease. Founded by p53 thought leader Dr. Arnold Levine and world-renowned virologist Dr. Thomas Shenk, in collaboration with co-founder Dr. David Mack, PMV Pharma possesses unique insights into p53 biology and the discovery of selective modulators of p53 and its pathway.
p53’s importance in human biology is profound: it is the most commonly mutated protein in human cancers with more than half of all tumors containing mutant p53. It is also a key cellular defense against viral infection and is known to suppress the replication of numerous viruses.
“PMV Pharmaceuticals has assembled a world-class team. Now is the time to apply the knowledge accumulated over decades of p53 research into the discovery and development of life changing medicines. The era of big biology is upon us, and I expect PMV Pharma to be a major player in a new generation of medicines,” Steve Holtzman said.
Steve Holtzman currently serves as Executive Vice President, Corporate Development for Biogen Idec where he is responsible for Business Development and M&A, and Program Leadership & Management of the company’s late-stage product candidates and marketed products. Prior to joining Biogen Idec, Mr. Holtzman served as the Founder, CEO and Chair of the Board of Directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. Mr. Holtzman was an early leader and Chief Business Officer of Millennium Pharmaceuticals, Inc., now a subsidiary of Takeda Pharmaceuticals. Prior to joining Millennium, he was a Founder, a member of the Board, and the Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical and pharmaceutical applications of transgenic technology.
Steve received his B.A. in Philosophy (1976) from Michigan State University and his B.Phil. graduate degree in Philosophy (1979) from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.
About PMV Pharma
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer and infectious disease. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma received initial funding from premier venture capital firm InterWest Partners and has corporate operations in Redwood City, California and Research and Development in Doylestown, Pennsylvania.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
